Zepp Health Corporation’s SEC filings document a foreign private issuer whose American depositary shares each represent sixteen Class A ordinary shares. The company files current reports on Form 6-K and annual reporting on Form 20-F covering its smart wearable and health technology business, including Amazfit-branded products and the Zepp Digital Management Platform.
The filings and exhibits record unaudited operating results, revenue and margin commentary, cash, inventory and loan balances, product launches, capital-structure actions, risk factors, governance matters and ADR-related disclosure. They also provide formal disclosure around periodic results releases and other material information furnished by the company to U.S. markets.
Zepp Health Corporation reported rapid growth for the fourth quarter and full year 2025, pairing strong sales momentum with narrower losses. Fourth quarter 2025 revenue reached US$85.2 million, up 43.0% year over year and 12.4% sequentially, while gross margin climbed to a record 40.4% from 36.8% a year earlier, helped by a richer Amazfit product mix and sustained pricing.
Despite higher selling, marketing and general administrative costs, including US$5.2 million in special provisions and brand/IP expenses, profitability improved. Adjusted operating loss in the quarter shrank to US$2.7 million from US$7.4 million, and net loss fell to US$11.0 million from US$36.9 million. For full year 2025, revenue rose 41.8% to US$258.9 million, with net loss reduced to US$40.1 million from US$75.7 million and adjusted net loss down to US$31.5 million from US$56.7 million. Cash and restricted cash totaled US$112.9 million at year-end, inventory was US$72.8 million, cumulative debt retired since 2023 reached US$58.2 million, and the company has repurchased US$16.2 million (about 2.2 million ADSs) under a buyback program extended through November 2026. Management guides first quarter 2026 revenue of US$50.0–55.0 million, implying 30% to 43% year-over-year growth.
Zepp Health Corp director Lam Sai Wai Alain filed an initial Form 3, which is a statement of beneficial ownership of the company’s securities. The filing does not report any buy or sell transactions and serves to formally register his insider ownership status with regulators.
Zepp Health Corp director Zhang HongJiang filed an initial statement of beneficial ownership on Form 3. The filing identifies him as a director of Zepp Health but does not report any share transactions or changes in ownership, serving as a baseline disclosure of his status as an insider.
FIL Limited and related entities have disclosed a significant stake in Zepp Health Corp. As of 12/31/2025, they report beneficial ownership of 10,012,096 Class A common shares, representing 8.7% of the class. These shares are held with sole power to dispose but no shared voting or dispositive power.
The filing notes that one or more other persons have rights to dividends or sale proceeds, including Fidelity Funds - China Focus, whose interest was 5,998,048 Class A shares, or 5.2% of the outstanding class as of 12/31/2025. The securities are stated as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Zepp Health.
Zepp Health Corp (ZEPP): Schedule 13G/A ownership update
Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen reported beneficial ownership of 8,777,008 Class A ordinary shares of Zepp Health, equal to 7.6% of the class, as of September 30, 2025. The position is held in the form of 548,563 ADSs, with each ADS representing 16 Class A ordinary shares.
The reporting persons have shared voting and dispositive power over 8,777,008 shares and no sole voting or dispositive power. They certified the securities were not acquired to change or influence control of the issuer.
Zepp Health Corporation was the subject of a Schedule 13G reporting passive beneficial ownership by Millennium-affiliated entities and Integrated Core Strategies.
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each reported beneficial ownership of 6,634,592 Class A Ordinary Shares, representing 5.8% of the class, with shared voting and dispositive power and 0 sole power. Integrated Core Strategies (US) LLC reported beneficial ownership of 6,285,648 shares, or 5.5%, also with shared voting and dispositive power and none sole.
The certification states the securities were not acquired and are not held for the purpose of changing or influencing control. The CUSIP (98945L204) applies to the issuer’s American Depositary Shares, and each ADS represents 16 Class A Ordinary Shares.
Allspring Global Investments Holdings, LLC filed an amendment to a Schedule 13G reporting beneficial ownership of 3,324,544 ADRs of Zepp Health Corp (symbol ZEPP), representing 2.9% of the class. The filing states these shares are held in the ordinary course of business with sole voting and sole dispositive power over all reported shares, and were not acquired to influence control of the issuer. The record lists client accounts of investment advisers affiliated with Allspring as the owners of record and confirms no client is known to hold more than 5% individually. The filing is signed by a Senior Compliance Manager and cites related subsidiaries in Exhibit A.
Form 144 notice for Zepp Health Corp (ZEPP) reports a proposed sale of 3,000 American Depositary Receipts (ADRs) by a person who acquired them as founder shares on 02/08/2018 from the issuer. The filer plans to sell the ADRs through Piper Sandler & Co. on the NYSE, with an aggregate market value listed at $133,590 and an approximate sale date of 09/29/2025.
The filing states there were no other securities sold by the seller in the past three months and includes the seller's representation that they are not aware of any undisclosed material adverse information about the issuer. The number of ADRs outstanding is reported as 14,591,331, providing context for the size of the proposed sale relative to total shares.
Zepp Health Corporation filed a Form 144/A notifying a proposed sale of 11,000 American Depositary Receipts (ADRs) representing its common stock, with an aggregate market value of $411,070 and approximately 7,173,522 shares outstanding. The proposed approximate date of sale is 09/04/2025 on the NYSE. The ADRs to be sold were acquired on 02/12/2018 through vesting of a restricted stock award from Zepp Health Corporation; the original grant comprised 25,000 shares and payment was recorded as vesting of a restricted share award on the same date. The filer reports no securities sold in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information.
Zepp Health Corporation filed a Form 144/A notifying a proposed sale of 11,000 American Depositary Receipts (ADRs) representing its common stock, with an aggregate market value of $411,070 and approximately 7,173,522 shares outstanding. The proposed approximate date of sale is 09/04/2025 on the NYSE. The ADRs to be sold were acquired on 02/12/2018 through vesting of a restricted stock award from Zepp Health Corporation; the original grant comprised 25,000 shares and payment was recorded as vesting of a restricted share award on the same date. The filer reports no securities sold in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information.
Zepp Health Corporation filed a Form 144/A notifying a proposed sale of 11,000 American Depositary Receipts (ADRs) representing its common stock, with an aggregate market value of $411,070 and approximately 7,173,522 shares outstanding. The proposed approximate date of sale is 09/04/2025 on the NYSE. The ADRs to be sold were acquired on 02/12/2018 through vesting of a restricted stock award from Zepp Health Corporation; the original grant comprised 25,000 shares and payment was recorded as vesting of a restricted share award on the same date. The filer reports no securities sold in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information.
Zepp Health Corporation filed a Form 144/A notifying a proposed sale of 11,000 American Depositary Receipts (ADRs) representing its common stock, with an aggregate market value of $411,070 and approximately 7,173,522 shares outstanding. The proposed approximate date of sale is 09/04/2025 on the NYSE. The ADRs to be sold were acquired on 02/12/2018 through vesting of a restricted stock award from Zepp Health Corporation; the original grant comprised 25,000 shares and payment was recorded as vesting of a restricted share award on the same date. The filer reports no securities sold in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information.